Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WST-11 VTP in Esophagogastric Cancer With Dysphagia
NCT03133650Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Feb 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of padeliporfin VTP in esophageal cancer and dysphagia, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum tolerated laser fluence rate at 60 days. Started Apr 2017; status: active, not recruiting.
02
Drugs
padeliporfin VTP
03
Conditions
esophageal cancerdysphagia
Beyond the preview
Go deeper on NCT03133650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133650.